The workshop focused on topics related to Goal 1 of the update to the National Vaccine Plan (Research and Development), and on draft portions of the update recently released by federal agencies with coordination by NVPO. The draft plan can be read here (by clicking this link you are leaving the IOM website and will be directed to the HHS website).

The PowerPoint slides have been posted in the agenda below. Audio files will be added when they become available.

December 1, 2008: Second national stakeholder meeting, Irvine, CA
December 2, 2008: Closed committee meeting

Please direct any questions to vaccineplan@nas.edu.

Second National Stakeholder Meeting 

AGENDA
December 1, 2008 

National Academy of Sciences 
Beckman Center Huntington Room
100 Academy Way
Irvine, CA  

The 2008 Draft Strategic National Vaccine Plan is now available on the Department of Health and Human Services  National Vaccine Program Office website (click here to view--by clicking this link you are leaving the IOM website and will be directed to the HHS website).

Please note:
Panelists’ titles and affiliations are provided at the end of the agenda.
(*) denotes panelists who will give a formal presentation
(†) panelists who contributed to the draft National Vaccine Plan

8:30 am		Welcome and Committee Introductions Claire V. Broome Committee Chair
8:45 – 10:15 am		Panel 1: Encouraging scientific innovation (new vaccines, better vaccines) Moderator: Milagritos Tapia (IOM committee member) Panelists: Philip Dormitzer (Novartis) Kathryn Edwards (Vanderbilt University) Harry Greenberg (Stanford University)  Diane Griffin (Johns Hopkins University) Emil Gotschlich (Rockefeller University)  Ed Mocarski* (MedImmune) PowerPoint Presentation Barbara Mulach† (NIH/NIAID)  Stanley Plotkin* (Sanofi) PowerPoint Presentation Robin Robinson† (HHS/BARDA)  Rebecca Sheets† (NIH/NIAID) (via video) Justin Wright (BD Medical-Pharmaceutical Systems)
10:15 – 10:30 pm		Break
10:30 – 11:15 am		Panel 1 continued
11:15 am – 12:30 pm		Panel 2: Financing vaccine research and development  Moderator: Claire V. Broome (IOM committee chair)   Panelists: Harry B. Greenberg (Stanford University) Karl D. Handelsman (CMEA Ventures) David C. Kaslow (Merck) Leighton Read* (Alloy Ventures) Jeffrey Ulmer (Novartis)
12:30 – 1:30 pm		Lunch
1:30 – 3:00 pm		Panel 3: Addressing public needs and priorities  Moderator: Edgar Marcuse (IOM committee member) Panelists: Philip R. Dormitzer (Novartis) Kathryn Edwards (Vanderbilt University) David C. Kaslow (Merck)  Edward Mocarski (MedImmune) Stanley A. Plotkin* (Sanofi) PowerPoint Presentation Robin Robinson† (HHS/BARDA)
3:00 – 3:15 pm		Break
3:15 – 4:30 pm		Panel 4: Regulatory and other issues in developing and licensing novel processes, new technologies, etc. Moderator: Arthur Reingold (IOM committee member) Panelists:  David C. Kaslow (Merck)  Karen Midthun (FDA/CBER) Leighton Read (Alloy Ventures) Rebecca Sheets† (NIH/NIAID) (via video) Jeffrey Ulmer (Novartis)  Karl D. Handelsman (CMEA Ventures )
4:30 – 5:30 pm		Closing dialogue Moderator: Claire V. Broome (IOM committee chair)   Question to all stakeholders at the meeting What criteria would you use to determine what objectives should receive the greatest level of attention in the national vaccine plan? Final observations about the day’s discussions All panelists and audience members
5:30 pm		Adjourn
PANELIST TITLES AND AFFILIATIONS
	Philip Dormitzer Senior Director and Senior Project Leader (viral vaccine research) Novartis Vaccines and Diagnostics  Kathryn Edwards Sarah Sell Professor of Pediatrics Director, Division of Pediatric Clinical Research Vanderbilt University School of Medicine Harry B. Greenberg  Senior Associate Dean for Research and Training Stanford University School of Medicine  Professor of Medicine (Gastroenterology & Hepatology) Microbiology and Immunology, and  Staff Physician VA Palo Alto Health Care System  Diane Griffin Professor Alfred and Jill Sommer Professor and Chair in Molecular Microbiology and Immunology Johns Hopkins Bloomberg School of Public Health Emil Gotschlich  R. Gwin Follis-Chevron Professor Laboratory of Bacterial Pathogenesis and Immunology Rockefeller University  Karl D. Handelsman Managing Director CMEA Ventures  David C. Kaslow Vice President, Infectious Diseases and Vaccines Franchise Merck Research Laboratories  Karen Midthun Deputy Director, Center for Biologics Evaluation and Research Food and Drug Administration  Edward S. Mocarski, Jr.* Distinguished Fellow, MedImmune Vaccines MedImmune, AstraZeneca Professor Emeritus Stanford University  Robert W. Woodruff Professor in the Department of Microbiology and Immunology  Emory Vaccine Center, Emory University   Barbara Mulach†  Director, Office of Scientific Coordination and Program Operations Division of Microbiology and Infectious Diseases (DMID) National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health  Stanley Plotkin* Executive Advisor to CEO, Sanofi Pasteur Emeritus Professor of Pediatrics, University of Pennsylvania Leighton Read* General Partner Alloy Ventures  Robin Robinson† Director, Biomedical Advanced Research Development Authority U.S. Department of Health and Human Services CAPT Rebecca Sheets† Vaccine Scientific and Regulatory Specialist National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health Jeffrey Ulmer  Global Head, External Research  Novartis Vaccines and Diagnostics Justin Wright  Manager, Bio-Analytical Sciences  BD Medical-Pharmaceutical Systems